EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations
EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations
New appointments bring significant commercial experience with a focus on growing key strategic markets
新任命带来了丰富的商业经验,重点是不断增长的关键战略市场
Expands executive leadership in growing disruptive, robotics-based capital equipment in both Urology and Gynecology therapeutic applications
扩大在泌尿科和妇科治疗应用中不断增长的基于机器人的颠覆性资本设备领域的行政领导地位
LYON, France, June 3, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company's European and Middle Eastern commercial leadership. Mr. Desmedt has been appointed Vice President of Sales for Europe, Middle East, Africa, and India (EMEAI), and Mr. Fromm has been appointed General Manager for Switzerland and will oversee several strategic European territories.
法国里昂,2024年6月3日——机器人能量疗法领域的全球领导者EDAP TMS SA(纳斯达克股票代码:EDAP)今天宣布任命达米安·德斯梅特和亚历山大·弗洛姆,以进一步加强该公司在欧洲和中东的商业领导地位。Desmedt先生被任命为欧洲、中东、非洲和印度(EMEAI)销售副总裁,弗洛姆先生被任命为瑞士总经理,将监督多个欧洲战略地区。
"We are pleased to announce the expansion of our international commercial leadership team with the appointments of Damien Desmedt and Alexander Fromm, both of whom have extensive experience in commercializing disruptive, robotics-based capital equipment in the urology and gynecology markets," said Ryan Rhodes, Chief Executive Officer of EDAP TMS. "Our company's highest strategic priority is to grow our leading robotic HIFU technology platform, Focal One, by building out world-class commercial operations and infrastructure. Damien and Alex each possess a unique blend of talent, experience, and market knowledge that will help us grow Focal One adoption in the management of prostate cancer, while also preparing us to expand robotic HIFU applications for addressing a significant unmet need in women's health."
EDAP TMS首席执行官瑞安·罗德斯表示:“我们很高兴地宣布,任命了达米安·德斯梅特和亚历山大·弗洛姆,扩大了我们的国际商业领导团队,他们在泌尿科和妇科市场颠覆性、基于机器人的资本设备商业化方面拥有丰富的经验。”“我们公司的最高战略优先事项是通过建设世界一流的商业运营和基础设施,发展我们领先的机器人HIFU技术平台Focal One。Damien和Alex各拥有独特的才能、经验和市场知识,这将帮助我们在前列腺癌管理中提高Focal One的采用率,同时也为我们扩展机器人HIFU应用做好了准备,以满足女性健康领域尚未满足的重大需求。”
Damien Desmedt brings to EDAP more than 30 years of responsibility in leading companies in the field of innovations in healthcare with an expertise in the field of minimally invasive and robotic surgery. Prior to joining EDAP, Mr. Desmedt held several senior executive positions with Intuitive Surgical, most recently serving as Vice President and General Manager of Intuitive Surgical for key European markets, where he was responsible for driving top line growth while improving both business efficiencies and profits. During his tenure as Vice President and General Manager, Mr. Desmedt oversaw several strategic departments including sales, marketing, and market access which led to an increased number of da Vinci systems being placed and procedures being performed in key European markets. Earlier in his career, Mr. Desmedt served as Regional District Manager with Medtronic, where he successfully developed and led a sales and engineering team within the Cardiovascular Rhythm Management group. Prior to Medtronic, he served as Business Unit Manager Sales & Marketing with Covidien.
Damien Desmedt在医疗创新领域的领先公司工作了30多年,他在微创和机器人手术领域拥有专业知识,为EDAP带来了30多年的责任。在加入EDAP之前,Desmedt先生曾在Intuitive Surgical担任过多个高级管理职位,最近担任欧洲主要市场的Intuitive Surgical副总裁兼总经理,负责推动收入增长,同时提高业务效率和利润。在担任副总裁兼总经理期间,Desmedt先生监督了多个战略部门,包括销售、营销和市场准入,这导致在欧洲主要市场部署的达芬奇系统和执行的程序数量增加。在职业生涯的早期,Desmedt先生曾在美敦力担任区域经理,在那里他成功地组建并领导了心血管节律管理小组的销售和工程团队。在加入美敦力之前,他曾在Covidien担任销售和营销业务部门经理。
Alexander Fromm has over 25 years of experience within the medical device and technology industries and is a seasoned executive leader with a proven track record in general and commercial management. Mr. Fromm has significant experience across multiple technologic and therapeutic areas, including robotic surgery technologies in both laparoscopy and microsurgery (da Vinci & Symani). Mr. Fromm most recently served as General Manager, Switzerland for Duomed, where he was responsible for leading a team that facilitated the transition of newly acquired products and businesses into the Duomed Group. Prior to joining Duomed, Mr. Fromm was a Senior Director of Commercial Development with Medical Microinstruments MMI, where he was responsible for the successful launch of the Symani Microsurgical Robot in Europe. Prior to joining Medical Microinstruments MMI, Mr. Fromm spent several years with Intuitive Surgical, where he held multiple leadership roles across capital sales, clinical sales, and marketing. Prior to joining Intuitive Surgical, Mr. Fromm served as Business Unit Manager, Surgical Technologies with Medtronic.
亚历山大·弗洛姆在医疗器械和技术行业拥有超过25年的经验,是一位经验丰富的执行领导者,在一般和商业管理方面有着良好的往绩。弗洛姆先生在多个技术和治疗领域拥有丰富的经验,包括腹腔镜和显微外科的机器人手术技术(达芬奇) & 西玛尼)。弗洛姆先生最近担任Duomed瑞士总经理,负责领导一个团队,促进新收购的产品和业务向Duomed集团的过渡。在加入Duomed之前,弗洛姆先生曾在医疗微仪器MMI担任商业开发高级董事,负责赛玛尼的成功推出 欧洲的微外科机器人。在加入医疗微仪器MMI之前,弗洛姆先生在Intuitive Surgical工作了几年,在资本销售、临床销售和营销方面担任过多个领导职务。在加入Intuitive Surgical之前,弗洛姆先生曾在美敦力担任外科技术业务部经理。
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.
关于 EDAP TMS SA
作为全球超声治疗市场公认的领导者,EDAP TMS使用超声技术在全球范围内开发、制造、推广和分销用于各种病理的微创医疗设备。通过在其全系列机器人 HIFU 设备中结合成像和治疗模式方面的最新技术,EDAP TMS 推出了 Focal One 在欧洲和美国,可以满足理想的前列腺组织消融的所有要求。随着ExactVu微超设备的加入,EDAP TMS现在是唯一一家提供从诊断到前列腺癌局部治疗的完整解决方案的公司。EDAP TMS 还生产和分销其他医疗设备,包括 Sonolith i-move 碎石机和激光器使用体外冲击波碎石术(ESWL)治疗尿路结石。如需了解有关公司的更多信息,请访问 http://www.edap-tms.com, us.hifu-prostate.com 和 www.focalone.com。
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the "Securities Act") or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as "believe," "can," "contemplate," "could," "plan," "intend," "is designed to," "may," "might," "potential," "objective," "target," "project," "predict," "forecast," "ambition," "guideline," "should," "will," "estimate," "expect" and "anticipate," or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.
前瞻性陈述
除历史信息外,本新闻稿还包含适用的联邦证券法(包括1933年《美国证券法》(“证券法”)第27A条或1934年《美国证券交易法》第21E条所指的前瞻性陈述,这些陈述可以用 “相信”、“可以”、“计划”、“打算”、“旨在” 等词语来识别,“可能”、“可能”、“潜力”、“目标”、“项目”、“预测”、“目标”、“预测”、“目标”、“指导方针”、“应该”、“将”、“估计”、“期望” 和预期”,或这些表达方式和类似表达方式的负面含义,它们反映了我们对未来事件和财务业绩的看法。此类陈述基于管理层当前的预期,存在许多风险和不确定性,包括我们尚未知道或我们目前认为不重要的事项,并且无法保证预期的事件会发生,也无法保证设定的目标会真正实现。可能导致实际结果与前瞻性陈述中预期结果存在重大差异的重要因素包括,我们的HIFU设备的临床状况和市场接受度,我们的碎石和分销部门的持续市场潜力,以及与当前全球通货膨胀环境、不确定的全球经济、政治和金融环境、地缘政治不稳定、气候变化和COVID-19疫情等流行病或其他公共卫生危机相关的风险,及其对我们业务运营的相关影响,包括它们对我们业务或对我们设备和服务的需求的影响。
Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
可能导致这种差异的其他因素也可能包括但不限于公司向美国证券交易委员会提交的文件中描述的因素,特别是公司20-F表年度报告中的 “前瞻性信息警示声明” 和 “风险因素” 部分中描述的因素。
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
前瞻性陈述仅代表其发表之日。除法律要求外,我们没有义务根据新信息或未来发展对其进行更新。这些前瞻性陈述基于截至本新闻稿发布之日我们获得的信息、假设和估计,尽管我们认为此类信息构成了此类陈述的合理依据,但此类信息可能有限或不完整。
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
公司联系人
Blandine Confort
投资者关系 /法律事务
DEAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
投资者联系人
约翰·弗朗西斯
LifeSci 顾问有限公司
(917) 355-2395
jfraunces@lifesciadvisors.com